BioSpace News Archive

Biophytis SA (Nasdaq CM: BPTS, Euronext Growth Paris: ALBPS), (“Biophytis” or the “company”), today announces topline results for SARA-INT phase 2 study will be released in August 2021.

Helix BioPharma Corp. (TSX:HBP) (‘Helix’ or the ‘Company’), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Heman Chao has notified the Board of Directors of the Company of his intention to step down from the position of Chief Executive Officer (“CEO”), Chief Scientific Officer (“CSO”) and member of the Board, effective September 1, 2021

Today, the U.S. Food and Drug Administration approved Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn) as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the E. coli-derived asparaginase products used most commonly for treatment

Amedisys, Inc., a leading home health, hospice and personal care company, announced that it has signed a definitive agreement to acquire Contessa Health, a leader in hospital-at-home and skilled nursing facility at-home services.

Sarepta Therapeutics, Inc., the leader in precision genetic medicine for rare diseases, granted equity awards on June 30, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 2 individuals hired by Sarepta in June 2021.

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on the strategy for bringing rexlemestrocel-L to patients in the United States (US) with chronic low back pain (CLBP) due to degenerative disc disease (DDD) refractory to available therapies, including opioids.

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced the U.S. Food and Drug Administration (FDA) approval of Rylaze™

ERS Genomics Limited, and Nippon Gene Co., Ltd (Nippon Gene), a manufacturer of genetic engineering research reagents and diagnostic reagents for humans, animals, and plants, today announced a non-exclusive license agreement granting Nippon Gene access to ERS Genomics’ CRISPR/Cas9 patent portfolio.

Aligos Therapeutics, Inc. announced the pricing of its underwritten public offering of 4,400,000 shares of common stock at a public offering price of $19.00 per share.

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what Acumen believes to be a key underlying cause of Alzheimer’s disease, announced the pricing of its upsized initial public offering of 9,999,999 shares of common stock at a public offering price of $16.00 per share.